Th17 cells could facilitate wider clinical use of adoptive immunotherapy

(Medical University of South Carolina) Medical University of South Carolina (MUSC) investigators report that long-term expansion protocols for adoptive cancer immunotherapy do not compromise Th17 cells' effectiveness against large tumors, in the March 9, 2017 issue of JCI Insight. This finding is important because rapid expansion protocols that are used to produce sufficient CD8+ T cell numbers for adoptive cell therapy (ACT) degrade their effectiveness. These findings underscore that Th17 cell